EQS-News: Anteris Technologies Ltd
Anteris Technologies hails FDA early feasibility study approval for DurAVR™

06.12.2022 / 19:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


0.jpgContact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

Jonathan@proactiveinvestors.com


News Source: News Direct


06.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Anteris Technologies Ltd
United States
ISIN: AU000000AHZ5
EQS News ID: 1506645

 
End of News EQS News Service

1506645  06.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1506645&application_name=news&site_id=boersennews